When September turns teal for Ovarian Cancer Awareness Month, much of the conversation centers on ovarian cancer as a single disease.
But ovarian cancer is not just one disease.
There are several types of tumors that can develop in or around the ovaries, each with different characteristics, treatments, and patterns of recurrence. Among the lesser known is granulosa cell tumor, commonly called GCT.
It is a diagnosis many people will never encounter. For those who do, however, its rarity can become part of the challenge.
Granulosa cell tumors are rare cancers that usually develop in the tissues that support the ovaries. They belong to a group known as sex cord stromal tumors and can produce hormones, particularly estrogen. According to the National Cancer Institute, GCTs are generally slow growing and can occur in both adults and children.
Their rarity also means that the average person may know little, if anything, about them before a diagnosis.
And that raises an important question during Ovarian Cancer Awareness Month: How do we advocate for cancers that many people do not even know exist?
A Different Kind of Ovarian Cancer
Most ovarian cancers are epithelial cancers, which begin in cells associated with the outer surface of the ovary or related tissues. Granulosa cell tumors are biologically different.
They arise from granulosa cells, which normally play a role in ovarian function and hormone production.
The National Cancer Institute classifies granulosa cell tumors among ovarian sex cord stromal tumors. These tumors are uncommon compared with the much more prevalent epithelial ovarian cancers.
There are two principal forms, adult type and juvenile type. Adult type granulosa cell tumors account for the majority of cases, while juvenile granulosa cell tumors occur less frequently and tend to affect younger patients.
The distinction matters because rare cancers cannot simply be treated as smaller versions of more common cancers. Their biology, behavior and treatment considerations may differ.
When Hormones Become a Clue
One unusual characteristic of granulosa cell tumors is their ability to produce estrogen.
That hormonal activity can sometimes provide clues that something is happening within the body.
Abnormal vaginal bleeding is one possible presentation. Depending on a person’s age, hormonal changes associated with the tumor can appear differently. In younger patients, excess hormone production can contribute to unusually early puberty. In adults, menstrual irregularities or abnormal uterine bleeding may occur.
Other ovarian or pelvic tumors may also be associated with symptoms such as abdominal or pelvic discomfort, swelling, pressure or changes that can initially be attributed to other conditions.
None of these symptoms automatically means that someone has ovarian cancer or a granulosa cell tumor.
But persistent or unexplained changes deserve attention.
Knowing what is normal for your body is not about diagnosing yourself. It is about recognizing when something has changed enough to warrant a conversation with a healthcare professional.
The Challenge of Being Rare
Rare cancers create a particular problem for patients and healthcare systems.
When a disease affects relatively few people, there may be fewer large clinical studies, fewer specialists with extensive experience treating it and less public awareness surrounding the diagnosis.
Patients can suddenly find themselves learning an entirely new vocabulary while trying to understand pathology reports, treatment options and what their diagnosis could mean for the future.
Research on adult granulosa cell tumors has repeatedly acknowledged that their rarity limits the amount of high quality evidence available to guide treatment.
That makes specialized expertise particularly valuable.
For someone diagnosed with GCT, consultation with a gynecologic oncologist can help ensure that the diagnosis, staging and treatment plan are being evaluated by a physician who specializes in cancers of the female reproductive system.
Patients should also feel comfortable asking whether their pathology has been reviewed by specialists familiar with rare ovarian tumors, particularly when there is uncertainty surrounding a diagnosis.
A second opinion is not an act of distrust. With a rare disease, it can be another source of information.
Treatment Is Not One Size Fits All
Surgery is a central component of treatment for granulosa cell tumors, particularly when the disease can be removed.
What happens beyond surgery depends on factors including the patient’s age, stage of disease, whether the cancer has spread or returned, fertility considerations, previous treatment and other individual circumstances.
Chemotherapy, hormonal therapy, radiation or other approaches may be considered in certain situations, particularly for advanced or recurrent disease.
Because GCT is uncommon, researchers continue to investigate how best to treat patients whose cancer returns or cannot be completely addressed through surgery.
Clinical trials are also studying potential therapies specifically for ovarian granulosa cell tumors, an important reminder that rare cancer research continues to evolve.
The Long Story of Recurrence
There is another reason granulosa cell tumors deserve particular attention.
They can come back.
And recurrence does not always happen quickly.
Adult granulosa cell tumors are generally considered slow growing, but medical literature has documented recurrences many years after an initial diagnosis and treatment.
That makes long term follow up particularly important.
For some patients, follow up may include clinical examinations, imaging when appropriate and monitoring of tumor markers. Inhibin and anti Müllerian hormone may be useful markers for some patients, particularly when those markers were elevated when the cancer was initially diagnosed.
The appropriate surveillance plan is individual, which is why patients should discuss long term follow up directly with their oncology team.
Finishing treatment does not necessarily mean finishing the conversation.
For someone with a cancer known for the possibility of late recurrence, understanding the follow up plan matters.
What Should Patients Ask?
A rare diagnosis can make it difficult to know where to begin.
Patients diagnosed with a granulosa cell tumor may want to ask their healthcare team:
- What type of granulosa cell tumor do I have?
- What stage is my cancer?
- Has my pathology been reviewed by a gynecologic cancer specialist?
- Should I see a gynecologic oncologist or another specialist experienced with GCT?
- Was the tumor completely removed?
- Are additional treatments recommended?
- Were any tumor markers elevated when I was diagnosed?
- Will those markers be useful for monitoring me?
- What will my long term surveillance plan look like?
- What symptoms or changes should I report between appointments?
- Are there clinical trials or specialized centers I should know about?
These questions do not replace medical expertise. They help patients participate in the decisions being made about their care.
Awareness Must Include the Cancers We Rarely Discuss
Ovarian Cancer Awareness Month gives communities an opportunity to talk about symptoms, family history, research, treatment and the importance of listening to our bodies.
But meaningful awareness also requires us to acknowledge the diversity hidden within the words “ovarian cancer.”
Granulosa cell tumor may be rare, but rarity does not make a diagnosis less frightening, a patient’s questions less urgent or research less necessary.
For the person hearing “granulosa cell tumor” for the first time in a doctor’s office, the fact that most people have never heard of the disease offers little comfort.
That is why rare cancers belong in our awareness conversations, too.
At Byrd Cancer Education & Advocacy Foundation, we believe knowledge gives people a stronger foundation from which to ask questions and advocate for their care. No one should have to become an expert overnight simply because their diagnosis is uncommon.
Sometimes awareness begins with something as simple as learning the name of a cancer you did not know existed yesterday.
Today, that name is granulosa cell tumor.
Sources and Further Reading
- National Cancer Institute: The NCI defines granulosa cell tumor as a rare, usually slow growing cancer that most often forms in ovarian supporting tissues, can produce estrogen, and can occur in adults and children. National Cancer Institute: Granulosa Cell Tumor
- National Cancer Institute Clinical Trials: NCI describes ovarian granulosa cell tumors as accounting for roughly 5 to 7 percent of ovarian cancers and has documented clinical research specifically investigating treatment for recurrent adult type GCT. NCI: Ovarian Granulosa Cell Tumor Clinical Trial Information
- National Library of Medicine / PubMed: Published research has documented the potential for granulosa cell tumors to recur years after initial treatment, supporting the importance of long term follow up. PubMed: Granulosa Cell Tumors of the Ovary
